Watch CBS News

Bextra More Risks Than Benefits

The Food and Drug Administration asked pharmaceutical giant, Pfizer, to pull Bextra because of evidence that it increases the risk of heart attacks, strokes and a potentially fatal skin condition as well.

The Early Show medical correspondent Dr. Emily Senay explains what this means to you.

Bextra falls into a class of painkillers known as Cox-2 inhibtors that are very popular among people with arthritis. They have been in the news a lot lately, since the fall in fact, when one of them, Vioxx, was voluntarily pulled of the market because people who took it were found to be at an increased risk of heart attack and stroke.

The FDA now says that Bextra poses these same heart risks and in addition people taking the drug are ALSO at risk of a serious and sometimes fatal skin reaction.

So what should patients taking Bextra do?

Pfizer, which makes Bextra, suggests that anybody on the drug stop taking it and contact their physician about other treatment options.

The FDA now wants all the drugs in this class that are still on the market to carry what's known as a black box warning which states VERY clearly that these Cox- 2 inhibitors can increase your chances of cardiovascular problems.

Merck, which manufactures Vioxx, stands by their decision to voluntarily remove the drug from the market. However, the company maintains that Vioxx offers unique benefits among the COX 2 class of drugs

So how is it that Celebrex - another very popular Cox-2 is still on the market? In February, a panel that advises the FDA said that Celebrex seemed to have the fewest cardiovascular side effects of all the Cox-2 drugs. But as we mentioned earlier the government now wants it to carry one of those black box warning labels.

And the FDA has asked the makers of over-the counter pain relievers such as Advil and Aleve which are NOT COX 2 inhibitors, but which are still very popular with arthritis sufferers, to revise their labels saying that people who take them are at an increased risk of heart attacks, stroke, gastrointestinal bleeding and serious skin reactions.

The FDA says the the warning labels which will be placed on the over-the counter pain relievers will not be placed on aspirin because it had "special benefits when taken in low doses."

View CBS News In
CBS News App
Chrome Safari
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.